CRVO vs. FDMT, YMAB, ENGN, EPRX, GNFT, OGI, NLTX, PROK, ALMS, and ELDN
Should you be buying CervoMed stock or one of its competitors? The main competitors of CervoMed include 4D Molecular Therapeutics (FDMT), Y-mAbs Therapeutics (YMAB), enGene (ENGN), Eupraxia Pharmaceuticals (EPRX), GENFIT (GNFT), Organigram Global (OGI), Neoleukin Therapeutics (NLTX), ProKidney (PROK), Alumis (ALMS), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry.
CervoMed vs. Its Competitors
4D Molecular Therapeutics (NASDAQ:FDMT) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.
CervoMed has a net margin of -200.57% compared to 4D Molecular Therapeutics' net margin of -767,126.06%. 4D Molecular Therapeutics' return on equity of -33.26% beat CervoMed's return on equity.
4D Molecular Therapeutics presently has a consensus price target of $29.56, suggesting a potential upside of 577.88%. CervoMed has a consensus price target of $22.57, suggesting a potential upside of 198.17%. Given 4D Molecular Therapeutics' higher probable upside, equities analysts plainly believe 4D Molecular Therapeutics is more favorable than CervoMed.
99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 25.2% of CervoMed shares are held by institutional investors. 9.6% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 35.4% of CervoMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, 4D Molecular Therapeutics had 3 more articles in the media than CervoMed. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 1 mentions for CervoMed. CervoMed's average media sentiment score of 1.04 beat 4D Molecular Therapeutics' score of 0.49 indicating that CervoMed is being referred to more favorably in the news media.
CervoMed has higher revenue and earnings than 4D Molecular Therapeutics. CervoMed is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.
4D Molecular Therapeutics has a beta of 2.81, indicating that its stock price is 181% more volatile than the S&P 500. Comparatively, CervoMed has a beta of -0.75, indicating that its stock price is 175% less volatile than the S&P 500.
Summary
4D Molecular Therapeutics and CervoMed tied by winning 8 of the 16 factors compared between the two stocks.
Get CervoMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CervoMed Competitors List
Related Companies and Tools
This page (NASDAQ:CRVO) was last updated on 7/17/2025 by MarketBeat.com Staff
Free CRVO Stock Alerts